Sara Dellasala

1.2k total citations
33 papers, 695 citations indexed

About

Sara Dellasala is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Sara Dellasala has authored 33 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 28 papers in Genetics and 13 papers in Rheumatology. Recurrent topics in Sara Dellasala's work include Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Eosinophilic Disorders and Syndromes (13 papers). Sara Dellasala is often cited by papers focused on Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Eosinophilic Disorders and Syndromes (13 papers). Sara Dellasala collaborates with scholars based in United States, Georgia and Italy. Sara Dellasala's co-authors include Hagop M. Kantarjian, Gautam Borthakur, Jörge E. Cortes, Farhad Ravandi, Tapan M. Kadia, Guillermo Garcia‐Manero, Elias Jabbour, Sherry Pierce, Jan A. Burger and Mona Lisa Alattar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Sara Dellasala

30 papers receiving 688 citations

Peers

Sara Dellasala
Comparison fields: 5 of 47
  • Hematology 622
  • Genetics 388
  • Molecular Biology 207
  • Rheumatology 149
  • Oncology 92
Replace Gautam Borthakur with:
Gautam Borthakur United States
Daniela Cilloni Italy
Dushyant Verma United States
А К Голенков Russia
Nadine Besson United States
Patricia Martin‐Regueira United States
Prashanth Gopalakrishna Switzerland
J. Janssen Netherlands
Heather A. Bradeen United States
Angela Volkert United States
Gautam Borthakur United States View profile →
Citations per field, relative to Sara Dellasala
Sara Dellasala · 1×
Citations per year, relative to Sara Dellasala
Sara Dellasala · 1×

Countries citing papers authored by Sara Dellasala

Since Specialization
Citations

This map shows the geographic impact of Sara Dellasala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Dellasala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Dellasala more than expected).

Fields of papers citing papers by Sara Dellasala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Dellasala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Dellasala. The network helps show where Sara Dellasala may publish in the future.

Co-authorship network of co-authors of Sara Dellasala

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Dellasala. A scholar is included among the top collaborators of Sara Dellasala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Dellasala. Sara Dellasala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse
2024 ·Blood ·(unknown), Elias Jabbour, Jayastu Senapati, Fadi Haddad, Ghayas C. Issa, Koji Sasaki, Hussein A. Abbas, Sara Dellasala, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short
1
2
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
2024 ·Cancer ·Fadi Haddad, Koji Sasaki, Lewis Nasr, Nicholas J. Short, Tapan M. Kadia, Sara Dellasala, Jörge E. Cortes, Franck E. Nicolini, Ghayas C. Issa, Elias Jabbour, Hagop M. Kantarjian
8
3
Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase
2024 ·Clinical Lymphoma Myeloma & Leukemia ·Fadi Haddad, Koji Sasaki, Jayastu Senapati, Shimin Hu, Sara Dellasala, Ghayas C. Issa, (unknown), Hagop Kantarjian
3
4
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors
2023 ·American Journal of Hematology ·Elias Jabbour, Koji Sasaki, Fadi Haddad, Ghayas C. Issa, Guillermo Garcia‐Manero, Tapan M. Kadia, Nitin Jain, Musa Yılmaz, Courtney D. DiNardo, Keyur P. Patel, Rashmi Kanagal‐Shamanna, Richard Champlin, Issa F. Khouri, Sara Dellasala, Sherry Pierce, Hagop M. Kantarjian
15
5
More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
2022 ·Blood ·Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Kunhwa Kim, Jeffrey Skinner, Sara Dellasala, Yesid Alvarado, Alessandra Ferrajoli, Tapan M. Kadia, Musa Yılmaz, Naveen Pemmaraju, Guillermo Garcia‐Manero, Sherry Pierce, Elias Jabbour, Hagop Kantarjian
2
6
Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia
2022 ·Blood ·Álex Bataller, Koji Sasaki, Elias Jabbour, Ghayas C. Issa, Fadi Haddad, Jeffrey Skinner, Sara Dellasala, Guillermo Garcia‐Manero, Sherry Pierce, Hagop Kantarjian
1
7
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
2022 ·American Journal of Hematology ·Elias Jabbour, Koji Sasaki, Fadi Haddad, Ghayas C. Issa, Jeffrey Skinner, Sara Dellasala, Musa Yılmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip A. Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia‐Manero, Koichi Takahashi, Gautam Borthakur, Naveen Pemmaraju, Sherry Pierce, Hagop M. Kantarjian
25
8
Long‐term results of frontline dasatinib in chronic myeloid leukemia
2020 ·Cancer ·Abhishek Maiti, Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi, Srđan Verstovšek, Alessandra Ferrajoli, Zeev Estrov, Guillermo Garcia‐Manero, Tapan M. Kadia, Graciela M. Nogueras‐González, Jeffrey Skinner, (unknown), Sara Dellasala, Rajyalakshmi Luthra, Elias Jabbour, Susan O’Brien, Hagop M. Kantarjian
24
9
Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia
2020 ·Cancer ·Lucia Masárová, Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva, Srđan Verstovšek, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Tapan M. Kadia, Farhad Ravandi‐Kashani, Gautam Borthakur, Sara Dellasala, Zeev Estrov, Elias Jabbour, Hagop M. Kantarjian
13
10
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
2019 ·Blood ·(unknown), Hagop M. Kantarjian, Gautam Borthakur, Susan O’Brien, Srđan Verstovšek, Farhad Ravandi, Alessandra Ferrajoli, Jörge E. Cortes, Tapan M. Kadia, William G. Wierda, Guillermo Garcia‐Manero, Sara Dellasala, (unknown), Sherry Pierce, Mary Beth Rios, Elias Jabbour
3
11
Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up
2018 ·Blood ·Lucia Masárová, Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva, Srđan Verstovšek, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Tapan M. Kadia, Farhad Ravandi, Gautam Borthakur, Sara Dellasala, Elias Jabbour, Hagop M. Kantarjian
1
12
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations
2018 ·International Journal of Hematology ·Kiran Naqvi, Jörge E. Cortes, Raja Luthra, Susan O’Brien, William G. Wierda, Gautam Borthakur, Tapan M. Kadia, Guillermo Garcia‐Manero, Farhad Ravandi, Mary Beth Rios, Sara Dellasala, Sherry Pierce, Elias Jabbour, Keyur P. Patel, Hagop M. Kantarjian
10
13
Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting
2016 ·Blood ·Prajwal Boddu, Hagop M. Kantarjian, (unknown), Gautam Borthakur, Srđan Verstovšek, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Nitin Jain, Ahmad Alhuraiji, Jan A. Burger, Steven M. Kornblau, Sara Dellasala, Sherry Pierce, Elias Jabbour, Jörge E. Cortes
0
14
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
2016 ·British Journal of Haematology ·Preetesh Jain, Hagop M. Kantarjian, Koji Sasaki, Elias Jabbour, (unknown), Graciela Nogueras González, Srđan Verstovšek, Gautam Borthakur, William G. Wierda, Tapan M. Kadia, Sara Dellasala, Sherry Pierce, Farhad Ravandi, Susan O’Brien, Jörge E. Cortes
14
15
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
2016 ·Cancer ·Koichi Takahashi, Hagop M. Kantarjian, (unknown), Koji Sasaki, Preetesh Jain, Sara Dellasala, Farhad Ravandi, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Guillermo Garcia‐Manero, Elias Jabbour, Jörge E. Cortes
10
16
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
2015 ·The Lancet Haematology ·Preetesh Jain, Hagop M. Kantarjian, Mona Lisa Alattar, Elias Jabbour, Koji Sasaki, Graciela Nogueras González, Sara Dellasala, Sherry Pierce, Srđan Verstovšek, William G. Wierda, Gautam Borthakur, Farhad Ravandi, Susan O’Brien, Jörge E. Cortes
62
17
Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia
2015 ·Clinical Lymphoma Myeloma & Leukemia ·Binsah George, Jörge E. Cortes, Mónica Cabrero, Nitin Jain, Marina Konopleva, Michael Andreeff, (unknown), Sherry Pierce, Sara Dellasala, G. Borthakur, Elias Jabbour, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Farhad Ravandi
0
18
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
2014 ·Clinical Lymphoma Myeloma & Leukemia ·Naveen Pemmaraju, Hagop M. Kantarjian, Tapan M. Kadia, Jörge E. Cortes, Gautam Borthakur, Kate J. Newberry, Guillermo Garcia‐Manero, Farhad Ravandi, Elias Jabbour, Sara Dellasala, Sherry Pierce, Srđan Verstovšek
60
19
Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation
2013 ·Blood ·Maro Ohanian, Mark J. Levis, Stefan Faderl, Guillermo Garcia‐Manero, Elias Jabbour, Naval Daver, Sara Dellasala, Sherry Pierce, Jan A. Burger, Jörge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi
1
20
Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation
2012 ·Blood ·Farhad Ravandi, Mona Lisa Alattar, Mark J. Levis, Guillermo Garcia‐Manero, Mary Ann Richie, Naval Daver, Stefan Faderl, Michael Andreeff, Gautam Borthakur, Jan A. Burger, Tapan M. Kadia, Michael R. Grunwald, Sara Dellasala, Jörge E. Cortes, Hagop M. Kantarjian
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gautam Borthakur Breakdown of academic impact, for papers by Daniela Cilloni Breakdown of academic impact, for papers by Dushyant Verma Breakdown of academic impact, for papers by А К Голенков Breakdown of academic impact, for papers by Nadine Besson Breakdown of academic impact, for papers by Patricia Martin‐Regueira Breakdown of academic impact, for papers by Prashanth Gopalakrishna Breakdown of academic impact, for papers by J. Janssen Breakdown of academic impact, for papers by Heather A. Bradeen Breakdown of academic impact, for papers by Angela Volkert
Rankless by CCL
2026